Bank of New York Mellon’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $22.1M | Buy |
703,228
+20,939
| +3% | +$618K | ﹤0.01% | 1563 |
|
|
2026
Q1 | $16.9M | Sell |
682,289
-18,372
| -3% | -$438K | ﹤0.01% | 1629 |
|
|
2025
Q4 | $16.4M | Sell |
700,661
-3,278
| -0.5% | -$73K | ﹤0.01% | 1646 |
|
|
2025
Q3 | $13.9M | Sell |
703,939
-15,808
| -2% | -$325K | ﹤0.01% | 1751 |
|
|
2025
Q2 | $15.6M | Buy |
719,747
+9,822
| +1% | +$232K | ﹤0.01% | 1650 |
|
|
2025
Q1 | $17.2M | Sell |
709,925
-13,620
| -2% | -$307K | ﹤0.01% | 1577 |
|
|
2024
Q4 | $15.1M | Buy |
723,545
+9,194
| +1% | +$198K | ﹤0.01% | 1717 |
|
|
2024
Q3 | $14.2M | Sell |
714,351
-120,064
| -14% | -$2.23M | ﹤0.01% | 1751 |
|
|
2024
Q2 | $12.9M | Buy |
834,415
+16,960
| +2% | +$264K | ﹤0.01% | 1827 |
|
|
2024
Q1 | $13M | Buy |
817,455
+27,834
| +4% | +$419K | ﹤0.01% | 1827 |
|
|
2023
Q4 | $13.3M | Sell |
789,621
-545
| -0.1% | -$7.45K | ﹤0.01% | 1822 |
|
|
2023
Q3 | $9.24M | Sell |
790,166
-10,660
| -1% | -$143K | ﹤0.01% | 1989 |
|
|
2023
Q2 | $10.8M | Sell |
800,826
-18,172
| -2% | -$262K | ﹤0.01% | 1918 |
|
|
2023
Q1 | $13.6M | Sell |
818,998
-44,527
| -5% | -$735K | ﹤0.01% | 1760 |
|
|
2022
Q4 | $16.1M | Sell |
863,525
-52,871
| -6% | -$814K | ﹤0.01% | 1649 |
|
|
2022
Q3 | $11.8M | Buy |
916,396
+415,630
| +83% | +$4.93M | ﹤0.01% | 1809 |
|
|
2022
Q2 | $3.51M | Sell |
500,766
-68,776
| -12% | -$504K | ﹤0.01% | 2513 |
|
|
2022
Q1 | $4.72M | Buy |
569,542
+81,325
| +17% | +$575K | ﹤0.01% | 2456 |
|
|
2021
Q4 | $3.31M | Sell |
488,217
-167,300
| -26% | -$1.1M | ﹤0.01% | 2687 |
|
|
2021
Q3 | $3.48M | Buy |
655,517
+34,043
| +5% | +$186K | ﹤0.01% | 2682 |
|
|
2021
Q2 | $3.57M | Sell |
621,474
-14,435
| -2% | -$74.5K | ﹤0.01% | 2658 |
|
|
2021
Q1 | $2.93M | Buy |
635,909
+9,887
| +2% | +$39.3K | ﹤0.01% | 2704 |
|
|
2020
Q4 | $2.09M | Buy |
626,022
+195,689
| +45% | +$657K | ﹤0.01% | 2816 |
|
|
2020
Q3 | $1.28M | Buy |
430,333
+10,527
| +3% | +$41.2K | ﹤0.01% | 2969 |
|
|
2020
Q2 | $1.94M | Sell |
419,806
-7,996
| -2% | -$35.9K | ﹤0.01% | 2703 |
|
|
2020
Q1 | $1.65M | Sell |
427,802
-5,324
| -1% | -$21.9K | ﹤0.01% | 2646 |
|
|
2019
Q4 | $1.62M | Buy |
433,126
+45,432
| +12% | +$212K | ﹤0.01% | 2949 |
|
|
2019
Q3 | $2.06M | Buy |
387,694
+34,792
| +10% | +$185K | ﹤0.01% | 2748 |
|
|
2019
Q2 | $1.35M | Sell |
352,902
-106,849
| -23% | -$462K | ﹤0.01% | 3030 |
|
|
2019
Q1 | $2.34M | Buy |
459,751
+125,673
| +38% | +$369K | ﹤0.01% | 2700 |
|
|
2018
Q4 | $641K | Buy |
334,078
+25,498
| +8% | +$73K | ﹤0.01% | 3351 |
|
|
2018
Q3 | $1.17M | Buy |
308,580
+33,767
| +12% | +$106K | ﹤0.01% | 3177 |
|
|
2018
Q2 | $858K | Buy |
274,813
+37,388
| +16% | +$113K | ﹤0.01% | 3332 |
|
|
2018
Q1 | $568K | Sell |
237,425
-216,949
| -48% | -$721K | ﹤0.01% | 3529 |
|
|
2017
Q4 | $1.78M | Buy |
454,374
+240,537
| +112% | +$795K | ﹤0.01% | 2909 |
|
|
2017
Q3 | $539K | Buy |
213,837
+1,858
| +0.9% | +$5.1K | ﹤0.01% | 3556 |
|
|
2017
Q2 | $585K | Buy |
211,979
+142,803
| +206% | +$298K | ﹤0.01% | 3533 |
|
|
2017
Q1 | $135K | Buy |
69,176
+2,404
| +4% | +$3.06K | ﹤0.01% | 3965 |
|
|
2016
Q4 | $70K | Sell |
66,772
-4,266
| -6% | -$4.87K | ﹤0.01% | 4082 |
|
|
2016
Q3 | $77K | Sell |
71,038
-12,228
| -15% | -$11K | ﹤0.01% | 4082 |
|
|
2016
Q2 | $59K | Sell |
83,266
-159,932
| -66% | -$129K | ﹤0.01% | 4147 |
|
|
2016
Q1 | $285K | Sell |
243,198
-23,622
| -9% | -$36.6K | ﹤0.01% | 3662 |
|
|
2015
Q4 | $654K | Sell |
266,820
-655
| -0.2% | -$1.88K | ﹤0.01% | 3411 |
|
|
2015
Q3 | $803K | Sell |
267,475
-42,947
| -14% | -$185K | ﹤0.01% | 3321 |
|
|
2015
Q2 | $1.28M | Buy |
310,422
+218,221
| +237% | +$870K | ﹤0.01% | 3198 |
|
|
2015
Q1 | $399K | Sell |
92,201
-40
| -0% | -$144 | ﹤0.01% | 3696 |
|
|
2014
Q4 | $274K | Buy |
92,241
+25,285
| +38% | +$69.4K | ﹤0.01% | 3808 |
|
|
2014
Q3 | $222K | Sell |
66,956
-56,939
| -46% | -$149K | ﹤0.01% | 3867 |
|
|
2014
Q2 | $313K | Buy |
123,895
+658
| +0.5% | +$1.41K | ﹤0.01% | 3732 |
|
|
2014
Q1 | $279K | Buy |
123,237
+21,874
| +22% | +$45.7K | ﹤0.01% | 3760 |
|
|
2013
Q4 | $198K | Hold |
101,363
| – | – | ﹤0.01% | 3856 |
|
|
2013
Q3 | $309K | Buy |
+101,363
| New | +$171K | ﹤0.01% | 3671 |
|
Other funds holding CPRX
GT
N
GCM
Bank of New York Mellon's CPRX Position: Q2 2026 in Review
Bank of New York Mellon increased its Catalyst Pharmaceutical (CPRX) stake by 3.1% in Q2 2026, buying an estimated $618K and bringing the position to 703,228 shares worth $22.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1563.
Bank of New York Mellon first reported a position in CPRX in Q3 2013 and has held it in 52 quarters since. 222 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.
- Bank of New York Mellon held 703,228 shares of Catalyst Pharmaceutical worth $22.1M as of Q2 2026.
- Bank of New York Mellon bought 20,939 Catalyst Pharmaceutical shares in Q2 2026, an estimated $618K.
- Catalyst Pharmaceutical made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1563 holding.
- Bank of New York Mellon first reported a position in Catalyst Pharmaceutical in Q3 2013 and has held it in 52 quarters since.
- 222 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.